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Abstract
Background: This study investigated whether the vitreous fluid levels of soluble vascular endothelial growth factor
receptor-2 (sVEGFR-2), pigment epithelium-derived factor (PEDF), and soluble intercellular adhesion molecule 1
(sICAM-1) were associated with the occurrence of serous retinal detachment (SRD) in patients with central retinal
vein occlusion (CRVO).
Methods: We recruited 33 patients with CRVO and macular edema, as well as 18 controls with nonischemic ocular
diseases. Eighteen of the 33 patients with CRVO showed SRD on optical coherence tomography of the macula (defined
as subretinal accumulation of fluid with low reflectivity), while the other 15 patients only had cystoid macular edema
(CME, defined as hyporeflective intraretinal cavities). Retinal ischemia was evaluated by measuring the area of capillary
non-perfusion using fluorescein angiography and the public domain Scion Image program, while central macular
thickness (CMT) was examined by optical coherence tomography. Vitreous fluid samples were obtained during pars
plana vitrectomy and levels of the target molecules were measured by enzyme-linked immunosorbent assay.
Results: Ischemia was significantly more common in the SRD group (17/18 patients) than in the CME group
(5/15 patients) (P < 0.001). The vitreous fluid level of sICAM-1 increased significantly across the three groups from
the control group (4.98 ± 1.73 ng/ml) to the CME group (15.4 ± 10.1 ng/ml) and the SRD group (27.1 ± 17.7 ng/
ml) (ptrend< 0.001). The vitreous fluid level of sVEGFR-2 also showed a significant increase across the three groups
(1083 ± 541 pg/ml, 1181 ± 522 pg/ml, and 1535 ± 617 pg/ml, respectively, ptrend = 0.019). On the other hand, the
vitreous fluid level of PEDF showed a significant decrease across the three groups (56.4 ± 40.0 ng/ml, 24.3 ±
17.3 ng/ml, and 16.4 ± 12.6 ng/ml, respectively, ptrend< 0.001).
Conclusions: Higher levels of inflammatory factors (sICAM-1 and sVEGFR-2) and lower levels of anti-inflammatory
PEDF were observed in macular edema patients with SRD, suggesting that inflammation plays a key role in
determining the severity of CRVO.
Background
Central retinal vein occlusion (CRVO) is a common retinal
vascular disorder in patients with lifestyle-related diseases
such as hypertension and atherosclerosis. The initiating
event is thought to be thrombosis of the central retinal
vein [1]. Occlusion of this major outflow channel for the
retinal circulation markedly increases the intraluminal
pressure within the retinal veins, resulting in hemorrhage
and edema. Macular edema is the most common reason
for impaired vision in patients with CRVO [2]. Optical
coherence tomography (OCT) has demonstrated that
macular edema secondary to CRVO is frequently asso-
ciated with serous retinal detachment (SRD), cystoid
macular edema (CME), and inner retinal thickening [3,4].
The reasons why SRD is associated with CRVO are
unclear, but fluid leaking from damaged capillaries may
migrate to the subretinal space and cause serous detach-
ment. There is an increase of vascular endothelial growth
factor (VEGF) secretion when acute vascular occlusion
occurs in the retina [5]. We previously reported that
VEGF and interleukin-6 (IL-6) are involved in the patho-
genesis of SRD associated with CRVO [6], while Park et al.
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found that the aqueous humor level of VEGF was higher
in patients with branch retinal vein occlusion (BRVO) and
SRD than in those with BRVO and CME [7]. These find-
ing suggest that inflammatory factors are associated with
the occurrence of SRD in CRVO patients.
There is evidence that upregulation of various inflamma-
tory factors, including vascular endothelial growth factor
(VEGF), VEGF receptor-2 (VEGFR-2), intercellular adhe-
sion molecule (ICAM)-1, and interleukin (IL)-6, and/or
downregulation of anti-inflammatory factors like pigment
epithelium-derived factor (PEDF), which is a potent inhibi-
tor of angiogenesis [8], result in an increase of leukocyte-
endothelial interactions that contribute to breakdown of
the blood-retinal barrier (BRB) [9-11]. Blocking these
inflammatory factors has been shown to prevent retinal
leukostasis and an increase of retinal vascular permeability
in rats [9]. In addition, occurrence of macular edema in
patients with CRVO is associated with elevation of cyto-
kines involved in regulation of the inflammatory response
[11]. Although various inflammatory cytokines are reported
to influence vascular permeability in the eye and to be
related to macular edema in patients with CRVO, there is
little evidence regarding the relationship of SRD to inflam-
matory molecules such as soluble VEGFR-2 (sVEGFR-2),
soluble ICAM-1 (sICAM-1), and PEDF. sVEGFR-2 is pro-
duced as a result of alternative splicing of VEGFR-2
mRNA by retinal cells such as retinal glial Müller cells, and
is a functional and soluble form of VEGFR-2 that lacks
part of the intracellular domain [12]. ICAM-1 is normally
produced by retinal pigment epithelium cells [13], and
after adhesion molecules are shed by cells, its soluble form
(sICAM-1) can be detected in serum and body fluids
(including the vitreous fluid) [14]. sICAM-1 is formed by
the five extracellular immunoglobulin domains of mem-
brane-bound ICAM-1-after cleavage of these domains
from the cell surface, possibly by a matrix metalloprotei-
nase related to TNFa-converting enzyme or a human leu-
kocyte elastase [15]. PEDF is produced by retinal cells such
as retinal glial Müller cells and retinal pigment epithelial
cells [8,10]. We performed the present study to investigate
whether vitreous fluid levels of sVEGFR-2, sICAM-1, and




This study was performed in accordance with the Helsinki
Declaration of 1975 (1983 revision). The institutional
review boards of Tokyo Women’s Medical University and
Eguchi Hospital approved the protocol for collection and
testing of vitreous fluid. Written informed consent was
obtained from each subject following an explanation of
the purpose and potential adverse effects of the procedure.
Pars plana vitrectomy was performed at Tokyo Women’s
Medical University and Eguchi Hospital. Consecutive
patients presenting with CRVO between October 2007
and March 2011 were screened according to the following
inclusion and exclusion criteria. The inclusion criteria for
this study were (1) CME (including SRD) secondary to
CRVO in patients scheduled for pars plana vitrectomy,
including patients who had received retinal photocoagula-
tion, and (2) best-corrected visual acuity worse than 20/50
before surgery. Exclusion criteria were (1) previous ocular
surgery or vitreous injection of anti-VEGF agents and
triamcinolone acetonide, (2) diabetic retinopathy, (3) iris
rubeosis, and (4) a history of ocular inflammation or
vitreoretinal disease. Patients with iris rubeosis were
excluded because it has been reported that they have high
levels of cytokines [16], and the pathology of iris rubeosis
may be different from that of macular edema. Patients
with vitreous injection of anti-VEGF agents and triamcino-
lone acetonide were excluded because the molecules
(including VEGF) may be affected by anti-VEGF agents
and triamcinolone acetonide. Vitreous fluid samples were
obtained from 33 CRVO patients and 18 patients with
non-ischemic ocular disease (control group). These 18
patients without CRVO all had macular holes, but none of
them had associated proliferative vitreoretinopathy. The
CRVO patients comprised 16 men and 17 women aged
70.7 ± 8.2 years (mean ± SD), while the 18 patients in the
control group included 10 men and 8 women aged 69.7 ±
9.5 years. The mean duration of CRVO was 4.9 ± 2.7
months (range: 2 - 12 months). Hypertension was diag-
nosed in patients being treated with antihypertensive
agents or those who had a blood pressure > 140/90
mmHg [17]. As a result, 21 of the 31 patients (63.6%) had
hypertension. Before surgery, panretinal photocoagulation
was done to prevent neovascular glaucoma in 12 eyes
(mean: 1,156 shots; range: 598 to 1,801 shots).
All patients underwent complete ophthalmic examina-
tions including visual acuity, slit-lamp examination, fundu-
scopy, FA, and optical coherence tomography (OCT) 3
(Stratus model 3000; Carl Zeiss, Dublin, CA). Best-cor-
rected visual acuity was measured by Snellen visual acuity,
which was converted into logarithm of the minimum
angle of resolution (logMAR) for statistical comparison.
Fundus Examination
Patients were evaluated by careful biomicroscopic exami-
nation using a fundus contact lens. The fundus findings
were confirmed preoperatively by standardized fundus
color photography and fluorescein angiography (FA),
which was performed with a Topcon TRC-50EX fundus
camera, an image-net system (Tokyo Optical Co. Ltd.,
Japan), and a preset lens with a slit-lamp.
The preoperative and operative fundus findings were
recorded for each subject. A masked grader independently
assessed ischemic occlusion from fundus photographs.
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Areas of retinal photocoagulation were excluded when cal-
culating the size of the non-perfused region. When the
non-perfused area divided by the disc area yielded a value
of 10 or more, this was defined as indicating the presence
of retinal ischemia [18-20].
We divided patients into two groups according to the
presence of SRD confirmed by OCT examinations [7].
Serous retinal detachment was defined as typical subret-
inal fluid accumulation in neurosensory retinal detach-
ment with low or absent reflectivity anterior to a clearly
distinguishable outer band irrespective of the coexistence
of CME. We defined CME if there were hyporeflective
intraretinal cavities on OCT images. The central macular
thickness (CMT) was measured by OCT at scan lengths of
6.0 mm using a fast macular thickness map. Central macu-
lar thickness was defined as the distance between the inner
retinal surface and the retinal pigment epithelium includ-
ing SRD. Thickness of neurosensory retina was defined as
the distance between the inner and the outer neurosensory
retinal surfaces [21]; these were measured using the cali-
pers on the OCT machine.
Sample Collection
Samples of undiluted vitreous fluid (500 - 1,000 μl) were
collected at the start of vitrectomy by aspiration into a
1 ml syringe attached to the vitreous cutter before com-
mencing the intravitreal infusion of balanced salt solution.
The vitreous samples were immediately transferred into
sterile tubes and were rapidly frozen at -80°C.
Measurement of sICAM-1, sVEGFR-2, and PEDF Levels
Levels of sICAM-1 were measured in vitreous fluid
samples (from the same eye) as well as in plasma with
enzyme-linked immunosorbent assay using kits for human
sICAM-1 (Bender Med Systems, Burlingame, CA, USA)
[22]. PEDF was measured in vitreous and plasma samples
from the same patients with a human PEDF Sandwich
ELISA kit (Chemicon International, Temecula, CA) [23].
Vitreous fluid levels of sVEGFR-2 were also determined by
ELISA according to the manufacturer’s instructions (Mit-
subishi Chemical Medience Corporation, Tokyo, Japan)
[24]. A volume of 100 μL of assay diluent RD 1W (R&D
Systems) and 100 μL of either the standard control or a 5-
fold diluted vitreous fluid sample were added to each well
of the ELISA plate, which was incubated for 2 hours on a
shaker at room temperature and washed. Then a horserad-
ish peroxidase-labeled polyclonal antibody for sVEGFR-2
was added to each well, followed by incubation for 2 hours
with shaking at room temperature and washing of the
plate. Next, the substrate solution (200 μL), color reagent
A (hydrogen peroxide; R&D Systems), and color reagent B
(chromogen; R&D Systems) were mixed together in equal
volumes and added to each well, after which the plate
was incubated for 30 minutes at room temperature in
darkness. Finally, 50 μL of stop solution (2N sulfuric acid;
R&D Systems) was added, and the absorbance was deter-
mined at 450 nm (with correction at 540 or 570 nm) by
using a microplate reader. The levels of these molecules in
the vitreous fluid were within the detection ranges of
the assays, with the minimum detectable concentration
being 3.3 ng/ml for sICAM-1 (intra-assay coefficient of
variation (CV): 5.4%, inter-assay CV: 7.8%), 1.95 ng/ml for
PEDF (intra-assay CV: 5.4%; inter-assay CV: 7.9%) and
78.1 pg/ml for sVEGFR-2 (intra-assay CV: 5.5%, inter-
assay CV: 6.9%).
Statistical Analysis
All analyses were performed with SAS System 9.1 soft-
ware (SAS Institute Inc., Cary, North Carolina, USA).
Data are presented as frequencies or as the mean ± SD.
Student’s t-test was employed to compare normally dis-
tributed unpaired continuous variables between the two
groups and the one-way-ANOVA was used among three
groups. Normality of the distribution of data was
assessed with the Kolmogorov-Smirnov test. The chi-
square test or Fisher’s exact test was used to compare
nominal variables. To assess the trends of sVEGFR-2,
sICAM-1, and PEDF levels among the groups, a linear
regression model was used. A two-tailed P value of less
than 0.05 indicated statistical significance.
Results
A profile of the subjects is given in Table 1. The 33
CRVO patients were classified into 15 with CME (CME
group) and 18 with SRD (SRD group). The mean age and
the female/male ratio were similar among the three
groups (P = 0.900 and P = 0.874, respectively), but there
was a significant difference in the prevalence of hyperten-
sion (P = 0.017). The duration of CRVO was similar in
the CME and SRD groups (P = 0.704). The incidence of
ischemia was significantly higher in the SRD group than
in the CME group (P < 0.001), but performance of pan-
retinal photocoagulation did not show a significant differ-
ence between these two groups (P = 0.064).
There was a significant increase in the vitreous fluid
level of sICAM-1 across the three groups from the con-
trol group (4.98 ± 1.73 ng/ml) to the CME group (15.4 ±
10.1 ng/ml) and the SRD group (27.1 ± 17.7 ng/ml)
(ptrend< 0.001; Figure 1). There was also a significant
increase in the vitreous fluid level of sVEGFR-2 across
the three groups (1083 ± 541 pg/ml, 1181 ± 522 pg/ml,
and 1535 ± 617 pg/ml, respectively, ptrend = 0.019)
(Figure 2). Conversely, the PEDF level showed a signifi-
cant decrease across the three groups (56.4 ± 40.0 ng/ml,
24.3 ± 17.3 ng/ml, and 16.4 ± 12.6 ng/ml, respectively,
ptrend< 0.001) (Figure 3).
No significant differences were noted with regard to
the vitreous levels of sICAM-1, sVEGFR-2, or PEDF
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between the 12 patients who received preoperative ret-
inal photocoagulation and the 21 patients who did not
(P = 0.396, P = 0.125, and P = 0.176, respectively).
Discussion
The present study demonstrated a significant increase in
the vitreous fluid level of sICAM-1 across the three
groups from the control group to the CME group and
the SRD group. It has been reported that CME is the
most common form of macular edema secondary to
CRVO, and SRD is often found to be associated with
CME in CRVO patients who undergo OCT [3,4]. Vascu-
lar leakage from congested veins or capillaries could be a
major source of subretinal fluid and SRD secondary to
CRVO may arise from transudation of intraretinal extra-
cellular fluid into the subretinal space [3,4]. The foveal
architecture probably also has an influence, especially the
Müller cell cone [4]. In the present study, retinal ische-
mia was significantly more common in the SRD group
than the CME group, suggesting that retinal ischemia
may influence the occurrence of SRD. We previously
reported that an increase of intraocular sICAM-1 is asso-
ciated with increased vascular permeability and with
more severe retinal ischemia in CRVO patients [22].
These findings and the present results suggest that
increased vascular permeability due to upregulation of
sICAM-1 may contribute to SRD in patients with CRVO,
as has already been demonstrated for VEGF [6]. In addi-
tion, increased ICAM-1 expression by endothelial cells
would increase leukocyte migration and result in the
accumulation of sICAM-1 in serum and body fluids such
as the vitreous fluid [14]. The results of the present study
suggest that leukocyte migration is a feature of SRD.
Therefore, an alternative explanation is that systemic
Table 1 Clinical Features of Patients With CRVO
Findings Control (N = 18) CME (N = 15) SRD (N = 18) P-value
Age (years) 69.7 ± 9.5‡ 71.1 ± 8.7‡ 70.3 ± 8.1‡ 0.900
Gender(female/male) 8/10 8/7 9/9 0.874
Hypertension 4 10 11 0.017
Duration of CRVO (months) N/A 5.2 ± 2.9‡ 4.8 ± 2.6‡ 0.704
Ischemia N/A 5 17 < 0.001
Panretinal photocoagulation N/A 8 4 0.064
CRVO = central retinal vein occlusion; CME = cystoid macular edema; SRD = serous retinal detachment
‡ Mean ± standard deviation (SD).CRVO = central retinal vein occlusion. N/A = NotApplicable.
Figure 1 Vitreous fluid levels of soluble intercellular adhesion
molecule-1 (sICAM-1) in the CRVO patients and controls.
Horizontal bars in the box plots display 10%, 25%, 50% (median),
75%, and 90%, while the square plot indicates the mean value for
sICAM-1.
Figure 2 Vitreous fluid levels of soluble vascular endothelial
growth factor receptor-2 (sVEGFR-2) in the CRVO patients and
controls. Horizontal bars in the box plots display 10%, 25%, 50%
(median), 75%, and 90%, while the square plot indicates the mean
value for sVEGFR-2.
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athrosclerosis or vasculitis causes CRVO, after which
sICAM-1 enters the vitreous fluid due to increased vas-
cular permeability. Thus, sICAM-1 entering the vitreous
fluid could contribute to the complications of CRVO in
patients with athrosclerosis or vasculitis, but further
investigation would be required to confirm this.
The present study also identified a significant increase in
the vitreous fluid level of sVEGFR-2 across the three
groups from the control group to the CME group and the
SRD group. It has been reported that activation of VEGFR-
2 contributes to disruption of tight junctions by decreasing
occludin expression [25]. In addition, Ojima et al. [26]
reported that VEGF-induced phosphorylation of VEGFR-2
and activation of downstream signaling are related to
breakdown of the BRB. Furthermore, suppression of
VEGFR-2 signaling inhibits VEGF-mediated loss of tight
junction proteins in retinal endothelial cells and blocks the
VEGF-mediated increase of retinal vascular leakage [27].
Moreover, VEGFR-2/Src kinase inhibitors have been
shown to prevent a VEGF-induced increase of vascular
permeability and reduce retinal edema in an experimental
model of retinal ischemia [28]. Such inflammatory effects
of sVEGFR-2 may contribute to an increase of retinal vas-
cular permeability. We previously reported that the pro-
duct of vitreous sVEGFR-2 and VEGF levels (sVEGFR-2 ×
VEGF) was significantly correlated with the severity of
macular edema in CRVO patients, although the vitreous
fluid level of sVEGFR-2 alone was not [24]. This suggests
that an increase of sVEGFR-2 along with up-regulation of
VEGF is associated with more severe macular edema.
Accordingly, retinal vascular permeability may increase
because of the upregulation of both sVEGFR-2 and VEGF,
contributing to the development of SRD in patients with
CRVO.
Finally, we found that the PEDF level showed a significant
decrease across the three groups from the control group to
the CME group and the SRD group. In contrast, Park et al.
[7] reported no significant difference in the aqueous humor
level of PEDF between SRD and CME patients. However,
measurement of these molecules in vitreous fluid is more
accurate for investigating changes of retinal physiology
than measurement in aqueous humor, which could account
for difference between our findings and those of Park.
PEDF is a negative acute-phase protein, so an increase of
PEDF would probably inhibit retinal inflammation and pre-
vent breakdown of the BRB. Intravitreal injection of PEDF
was reported to significantly reduce retinal vascular perme-
ability in an animal model, along with an increase in the
retinal level of occludin, which is a major component of
endothelial tight junctions [10]. In the same model, the ret-
inal levels of inflammatory factors (including VEGF and
ICAM-1) were significantly lower in PEDF-treated eyes
than in control eyes [10]. In cultured retinal endothelial
cells, PEDF ameliorates the VEGF-induced increase of per-
meability, consistent with in vivo findings [29]. In addition,
retinal Müller cells show a significant increase of VEGF
production after silencing of PEDF [10]. These results and
the present findings suggest that PEDF acts as an endogen-
ous inhibitor of inflammation which blocks the expression
and activity of various inflammatory molecules, thus contri-
buting to a reduction of vascular permeability. Accordingly,
an increase of vascular permeability secondary to downre-
gulation of PEDF may contribute to the development of
SRD in patients with CRVO. In addition, the above-men-
tioned findings taken together with the results of this study
suggest that PEDF may normally inhibit retinal inflamma-
tion (control group) and prevent breakdown of the BRB,
while PEDF expression seems to be reduced in CRVO
patients.
In the present study, we found high levels of inflamma-
tory factors like sICAM-1 and a low level of anti-inflamma-
tory PEDF in CRVO patients with SRD, suggesting that
inflammation is active in these patients. Therefore, anti-
VEGF therapy that only reduces the ocular level of free
VEGF may be inadequate for CRVO patients with SRD.
Addition of triamcinolone acetonide could be more effec-
tive because it modulates vascular permeability by downre-
gulating inflammatory factors (ICAM-1 [30] and VEGFR-2
[31]) and by upregulating anti-inflammatory factors such
as PEDF [32]. Thus, assessing the pathologic features of
each patient (such as the presence or absence of SRD) may
allow us to select the best treatment strategy for macular
edema associated with CRVO, but a randomized
Figure 3 Vitreous fluid levels of pigment epithelium-derived
factor (PEDF) in the CRVO patients and controls. Horizontal bars
in the box plots display 10%, 25%, 50% (median), 75%, and 90%,
while the square plot indicates the mean value for PEDF.
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prospective clinical trial of each therapy would be required
to confirm this.
The present study had the following limitations. The
first is that some of our subjects received laser treatment,
which could have influenced the vitreous fluid levels of
sVEGFR-2 and VEGF. Although we found no significant
difference of vitreous sVEGFR-2 and VEGF levels between
the 12 patients with preoperative retinal photocoagulation
and the 21 patients who did not receive it, further investi-
gation will be required to confirm the influence of retinal
photocoagulation on vitreous fluid levels of sVEGFR-2
and VEGF. Second, we performed vitrectomy for macular
edema because it has been reported that vitrectomy can
improve macular edema and visual acuity in CRVO
patients [33,34]. However, current standard care for
CRVO includes anti-VEGF agents since the CRUISE trial
showed improvement of visual acuity with ranibizumab
therapy [35]. This suggests that vitrectomy should prob-
ably be considered following the failure of anti-VEGF ther-
apy, but such a treatment strategy for CRVO needs to be
investigated in the future. Third, there is no evidence how
changes of various molecules (including VEGFR-2) in the
vitreous fluid are reflected in the retinal tissues because
the function of sVEGFR-2 in the vitreous remains
unknown. Further studies of VEGFR-2 in this disease
would be needed to determine whether its kinetics in the
vitreous fluid actually reflect those in the retinal tissues of
CRVO patients.
Conclusions
In conclusion, we found that the vitreous fluid levels of
sICAM-1 and sVEGFR-2 were higher in CRVO patients
who had SRD compared with those who had CME, while
the vitreous PEDF level was lower in patients with SRD.
The higher levels of inflammatory factors (sICAM-1 and
sVEGFR-2) and lower levels of anti-inflammatory PEDF
observed in macular edema patients with SRD suggest
that inflammation may have an important influence on
the severity of CRVO.
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